Evidence map›Paper›PMID 34271861›Full record

ArticleBMC cancer2021

Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer.

Anna Hung, Kyung Min Lee, Julie A Lynch, Yanhong Li, Pradeep Poonnen, Olga V Efimova, Bradley J Hintze, Trudy Buckingham, Candice Yong, Brian Seal and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Anna HungDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. anna.hung@duke.edu.
Kyung Min LeeDepartment of Veteran Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.
Julie A LynchDepartment of Veteran Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.
Yanhong LiDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Pradeep PoonnenDepartment of Veteran Affairs Medical Center, Durham, NC, USA.
Olga V EfimovaDepartment of Veteran Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.
Bradley J HintzeDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Trudy BuckinghamAstraZeneca, Gaithersburg, MD, USA.
Candice YongAstraZeneca, Gaithersburg, MD, USA.
Brian SealAstraZeneca, Gaithersburg, MD, USA.
Michael J KelleyDepartment of Veteran Affairs Medical Center, Durham, NC, USA.
Shelby D ReedDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
AstraZeneca (United States) · USDuke University · USVA Salt Lake City Healthcare System · USClinical Research Institute · USDuke Medical Center · USDurham VA Medical Center · US

Funding

Improving Analysis of Endogenous Multimodal Treatments for Use in Geriatrics Health Outcomes StudiesI01HX002237 · VA · VA BOSTON HEALTH CARE SYSTEM · PI GARRIDO, MELISSA M · 2018 to 2021
–
HSRD VA SDR 02-237
6 · The paper itself

Abstract

backgroundThe Veterans Health Administration (VHA) is the largest integrated health care system in the United States (US). Among VHA patients, the rate of use of concurrent chemoradiation therapy (CCRT) among those with unresectable, stage III non-small cell lung cancer (NSCLC) is unknown. The objective was to report recent CCRT treatment patterns in VHA patients and identify characteristics associated with receipt of CCRT.

methodsUsing Department of Veteran Affairs (VA) Cancer Registry System data linked to VA electronic medical records, we determined rates of CCRT, sequential CRT (SCRT), radiation therapy (RT) only, chemotherapy (CT) only, and neither treatment.

resultsAmong 4054 VHA patients who met study criteria, CCRT rates slightly increased from 44 to 50% between 2013 and 2017. Factors associated with decreased odds of CCRT receipt compared to any other treatment included increasing age (adjusted odds ratio [aOR] per 10 years = 0.67; 95% CI: 0.60-0.76) and Charlson-Deyo comorbidity score (aOR = 0.94; 95% CI: 0.91-0.97). White race was associated with increased odds of CCRT receipt (aOR = 1.24; 95% CI: 1.004-1.53). In a chart review sample of 200 patients, less than half (n = 85) had a documented reason for not receiving CCRT. Among these, 29% declined treatment, and 71% did not receive CCRT due to "not being a candidate" for reasons related to frailty or lung nodules being too far apart for radiation therapy.

conclusionsCCRT rates among VHA patients with unresectable, stage III NSCLC slightly increased from 2013 to 2017; however in 2017, only half were receiving CCRT. Older patients and those with multiple comorbidities were less likely to receive CCRT and even when controlling for these factors, non-white patients were less likely to receive CCRT.

Indexed as

AgedCarcinoma, Non-Small-Cell LungChemoradiotherapyFemaleHumansLung NeoplasmsMaleNeoplasm StagingUnited StatesVeteransVeterans Health ServicesConcurrent and sequential ChemoradiationNon-small cell lung CancerVeterans health administration

Identifiers

PMID34271861
PMCPMC8285779
OpenAlexW3182249786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.